Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Hodgkin Disease × axatilimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myelomonocytic, Chronic 2 Breast Neoplasms 2 Primary Myelofibrosis 1 Neoplasm Metastasis 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1 Hodgkin Disease 1

Interventions

Cyclophosphamide 11 Nivolumab 8 Brentuximab Vedotin 8 pembrolizumab 7 fludarabine 6 Specimen Handling 6 Gemcitabine 6 Etoposide 6 Doxorubicin 6 Dacarbazine 6 Whole-Body Irradiation 5 Vinblastine 5 Melphalan 5 Granulocyte Colony-Stimulating Factor 5 Filgrastim 5 Dexamethasone 5 fludarabine phosphate 4 Stem Cell Transplantation 4 Mycophenolic Acid 4 Cytarabine 4 Vinorelbine 3 Magnetic Resonance Spectroscopy 3 Carmustine 3 Blood Specimen Collection 3 polatuzumab vedotin 2 pegylated granulocyte colony-stimulating factor 2 pegfilgrastim 2 X-Rays 2 Vincristine 2 Tacrolimus 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05723055 2025-11-26

NAHL

University of Utah

Phase 2 Recruiting

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡